Arbutus to Participate in Upcoming Investor Conferences - May 26, 2021
WARMINSTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following upcoming investor conferences:
Jefferies Virtual Healthcare Conference
- Wednesday, June 2, 2021 at 9:00 am ET (Fireside Chat)
- Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer
- Webcast Link
JMP Securities Life Sciences Conference - Virtual
- Thursday, June 17, 2021 at 11:00 am ET (Fireside Chat)
- Presenters: William Collier; Dr. Michael Sofia; Dr. Gaston Picchio; and David Hastings
- Webcast Link
The webcast links for the virtual fireside chats can also be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company’s website after the conference.
Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.
Investors and Media
William H. Collier
President and CEO
Investor Relations Consultant